alendronate has been researched along with Osteosclerosis in 7 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
Osteosclerosis: An abnormal hardening or increased density of bone tissue.
Excerpt | Relevance | Reference |
---|---|---|
"These results suggest that etidronate may 1) inhibit the entry of NBPs into cells related to inflammation and/or necrosis, 2) inhibit the binding of NBPs to bone hydroxyapatite, 3) at least partly eliminate (or substitute for) NBPs that have already accumulated within bones, and thus 4) if used as a substitution drug for NBPs, be effective at treating or preventing NBP-associated osteonecrosis of the jaw." | 3.76 | Inhibition of necrotic actions of nitrogen-containing bisphosphonates (NBPs) and their elimination from bone by etidronate (a non-NBP): a proposal for possible utilization of etidronate as a substitution drug for NBPs. ( Endo, Y; Funayama, H; Kawamura, H; Kumamoto, H; Kuroishi, T; Oizumi, T; Sasaki, K; Sugawara, S; Takahashi, H; Yamaguchi, K; Yamamoto, M; Yokoyama, M, 2010) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 7 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Campbell, GM | 1 |
Tower, RJ | 1 |
Damm, T | 1 |
Kneissl, P | 1 |
Rambow, AC | 1 |
Schem, C | 1 |
Tiwari, S | 1 |
Glüer, CC | 1 |
Zaman, MU | 1 |
Nakamoto, T | 1 |
Tanimoto, K | 1 |
Hamada, H | 1 |
Matsuo, A | 1 |
Koizumi, T | 1 |
Satomi, T | 1 |
Chikazu, D | 1 |
Oizumi, T | 1 |
Funayama, H | 1 |
Yamaguchi, K | 1 |
Yokoyama, M | 1 |
Takahashi, H | 1 |
Yamamoto, M | 1 |
Kuroishi, T | 1 |
Kumamoto, H | 1 |
Sasaki, K | 1 |
Kawamura, H | 1 |
Sugawara, S | 1 |
Endo, Y | 1 |
Treister, NS | 1 |
Friedland, B | 1 |
Woo, SB | 1 |
Chiu, CT | 1 |
Chiang, WF | 1 |
Chuang, CY | 1 |
Chang, SW | 1 |
O'Ryan, FS | 1 |
Lo, JC | 1 |
7 other studies available for alendronate and Osteosclerosis
Article | Year |
---|---|
Tracking the Progression of Osteolytic and Osteosclerotic Lesions in Mice Using Serial In Vivo μCT: Applications to the Assessment of Bisphosphonate Treatment Efficacy.
Topics: Alendronate; Animals; Bone Resorption; Cell Line, Tumor; Diphosphonates; Disease Progression; Female | 2018 |
A retrospective study of digital subtraction technique to detect sclerotic changes in alveolar bone on intraoral radiographs of bisphosphonate-treated patients.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Alveolar Process; Anatomic Landmarks; Bisphosphonate-As | 2013 |
A simple evaluation method for early detection of bisphosphonate-related osteonecrosis of the mandible using computed tomography.
Topics: Administration, Intravenous; Administration, Oral; Alendronate; Alveolar Process; Bisphosphonate-Ass | 2014 |
Inhibition of necrotic actions of nitrogen-containing bisphosphonates (NBPs) and their elimination from bone by etidronate (a non-NBP): a proposal for possible utilization of etidronate as a substitution drug for NBPs.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Ear, Extern | 2010 |
Use of cone-beam computerized tomography for evaluation of bisphosphonate-associated osteonecrosis of the jaws.
Topics: Adult; Aged; Alendronate; Bone Density Conservation Agents; Cone-Beam Computed Tomography; Diphospho | 2010 |
Resolution of oral bisphosphonate and steroid-related osteonecrosis of the jaw--a serial case analysis.
Topics: Actinomycosis; Administration, Oral; Aged; Aged, 80 and over; Alendronate; Anti-Bacterial Agents; Bo | 2010 |
Bisphosphonate-related osteonecrosis of the jaw in patients with oral bisphosphonate exposure: clinical course and outcomes.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Anti-Bacterial Agents; Antirheumatic Age | 2012 |